Bispecific antibodies developed for multiple myeloma currently target B-cell maturation antigen (BCMA), G protein–coupled receptor, class C, group 5, member D (GPRC5D), Fc receptor-like 5 (FcRL5), or CD-38. Here, CD38 is linked to plasma cell myeloma.